CCM
EW icon

CAAS Capital Management’s Edwards Lifesciences EW Stock Holding History

CAAS Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,800
Closed -$145K – 690
2023
Q2 		$170K Buy
+1,800
New +$156K 0.01% 548
2023
Q1 		– Sell
-7,000
Closed -$550K – 776
2022
Q4 		$522K Buy
+7,000
New +$539K 0.03% 403

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

CAAS Capital Management's EW Position: Q3 2023 in Review

CAAS Capital Management sold out of Edwards Lifesciences (EW) in Q3 2023, closing a stake of 1,800 shares — an estimated $145K sold.

CAAS Capital Management first reported a position in EW in Q4 2022 and held it in 2 quarters. The position peaked at $522K in Q4 2022. 1,219 funds tracked by Wall St. Rank hold EW as of Q3 2023.

  • CAAS Capital Management reported no remaining Edwards Lifesciences position as of Q3 2023 after selling out during the quarter.
  • CAAS Capital Management sold 1,800 Edwards Lifesciences shares in Q3 2023, an estimated $145K.
  • CAAS Capital Management first reported a position in Edwards Lifesciences in Q4 2022 and held it in 2 quarters.
  • CAAS Capital Management's Edwards Lifesciences position peaked at $522K in Q4 2022.
  • 1,219 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2023.

Based on CAAS Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.